Celcuity (CELC) EBIT (2016 - 2026)
Celcuity's (CELC) quarterly EBIT came in at -$49.2 million in Q4 2025, down 35.06% YoY from -$75.8 million in Q4 2024, and down 14.82% on a QoQ basis from -$42.8 million in Q3 2025.
Analysis
Celcuity (CELC) EBIT (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of EBIT data on file, last reported at -$49.2 million in Q4 2025.
- Quarterly EBIT fell 35.06% year-over-year to -$49.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$172.2 million (down 52.02% YoY) and the FY2025 annual result came in at -$172.2 million, down 52.02% from the prior year.
- EBIT eased to -$49.2 million in Q4 2025, from -$42.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$2.8 million in Q1 2021 to a low of -$49.2 million in Q4 2025.
- A 5-year average of -$21.0 million and a median of -$17.0 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2021 — EBIT sank 516.25% — and 2022, when it advanced 29.63%.
- Tracing CELC's EBIT over 5 years: stood at -$6.3 million in 2021, then tumbled by 84.14% to -$11.6 million in 2022, then plunged by 69.51% to -$19.7 million in 2023, then plunged by 84.65% to -$36.4 million in 2024, then plunged by 35.06% to -$49.2 million in 2025.
- The last three EBIT figures came in at -$49.2 million (Q4 2025), -$42.8 million (Q3 2025), and -$44.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Celcuity | 5.27 Bn | 5.27 Bn | - | -66.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -66.12 Mn |
| Dec 31, 2025 | -49.20 Mn |
| Sep 30, 2025 | -42.85 Mn |
| Jun 30, 2025 | -44.01 Mn |
| Mar 31, 2025 | -36.13 Mn |
| Dec 31, 2024 | -36.43 Mn |
| Sep 30, 2024 | -30.06 Mn |
| Jun 30, 2024 | -24.28 Mn |
| Mar 31, 2024 | -22.49 Mn |
| Dec 31, 2023 | -19.73 Mn |
| Sep 30, 2023 | -18.90 Mn |
| Jun 30, 2023 | -15.06 Mn |
| Mar 31, 2023 | -12.55 Mn |
| Dec 31, 2022 | -11.64 Mn |
| Sep 30, 2022 | -10.64 Mn |
| Jun 30, 2022 | -9.60 Mn |
| Mar 31, 2022 | -7.51 Mn |
| Dec 31, 2021 | -6.32 Mn |
| Sep 30, 2021 | -5.60 Mn |
| Jun 30, 2021 | -13.64 Mn |